Published in Oncotarget on February 20, 2015
Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep (2016) 0.84
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med (2016) 0.80
Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic. Oncotarget (2015) 0.80
microRNA-25 Inhibits Cell Apoptosis of Human Gastric Adenocarcinoma Cell Line AGS via Regulating CCNE1 and MYC. Med Sci Monit (2016) 0.78
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget (2016) 0.76
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS One (2017) 0.75
The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle (2017) 0.75
Cancer genome landscapes. Science (2013) 25.33
Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol Cell Biol (2000) 9.21
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
MYC on the path to cancer. Cell (2012) 8.65
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res (1995) 7.95
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 7.54
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
MYC oncogenes and human neoplastic disease. Oncogene (1999) 7.28
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell (2002) 5.47
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J (2004) 4.95
Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 4.55
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A (1999) 3.24
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med (2007) 2.65
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature (2012) 1.88
Making myc. Curr Top Microbiol Immunol (2006) 1.87
Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev (2003) 1.84
The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol (2007) 1.75
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol (2010) 1.69
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med (2014) 1.51
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell (2004) 1.42
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A (2003) 1.27
Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell (2013) 1.27
Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res (2011) 1.20
Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev (2012) 1.18
Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med (2009) 1.16
Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Rep (2013) 1.16
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell (2013) 1.08
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer (2014) 1.01
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res (2012) 0.99
Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas. Acta Oncol (2006) 0.95
Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle (2011) 0.90
Pooled shRNA screenings: experimental approach. Methods Mol Biol (2013) 0.88
Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med (2014) 0.86
Pooled shRNA screenings: computational analysis. Methods Mol Biol (2013) 0.82
Low frequency of hCDC4 mutations in human primary ovarian cancer. Gynecol Oncol (2007) 0.82